Validity of HB-EGF as target for human neuroblastoma therapy

Sung Ouk Nam, Fusanori Yotsumoto, Kohei Miyata, Ryota Souzaki, Tomoaki Taguchi, Masahide Kuroki, Shingo Miyamoto

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抜粋

Background/Aim: Neuroblastoma (NB) is the most common and lethal extracranial solid tumor in children. The present study aimed to verify that the heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a rational target in NB therapy. Material and Methods: We examined expression of EGFR ligands in four NB cell lines using 2-dimensional culture (DC) and 3DC conditions. To assess the anti-tumor effect of cross-reacting material 197 (CRM197), which is a specific inhibitor of HB-EGF, on NB cells, we also performed terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay to detect apoptotic cells. Results: HB-EGF was predominantly expressed in two out of four NB cell lines under 2DC and 3DC conditions. CRM197 significantly induced apoptosis of NB cells with high HB-EGF expression. Conclusion: HBEGF plays an important role in neuroblastoma tumorigenesis and CRM197 showed an effective antitumor effect in neuroblastoma cells.

元の言語英語
ページ(範囲)4433-4440
ページ数8
ジャーナルAnticancer research
35
発行部数8
出版物ステータス出版済み - 8 1 2015

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Nam, S. O., Yotsumoto, F., Miyata, K., Souzaki, R., Taguchi, T., Kuroki, M., & Miyamoto, S. (2015). Validity of HB-EGF as target for human neuroblastoma therapy. Anticancer research, 35(8), 4433-4440.